Stephan Goldenbaum has worked in biotech since 2003. Until 2017, he was head of sales in Europe, Africa and the Middle East working for QIAGEN, a leading global biotech company. From 2018 until joining Solis BioDyne, Goldenbaum worked on developing sales channels in the large Germany-based biotech company Eppendorf Group. Goldenbaum holds Master’s degrees in biology and business integration.
According to Stephan Goldenbaum, he considers his task to be the improvement of Solis BioDyne’s product development and sales, growing the company’s export volumes and expanding its network of partnerships. “We operate in the market of reagents, where export volumes are measured in millilitres. This means even more work needs to be done in research and development, that drives export. We want to work even more closely with research institutions, primarily the University of Tartu with whom we already have close relations. Solis BioDyne wants to continue to be one of the most attractive employers in Estonia for students and scientists of life-sciences. For example, we are very interested in recruiting people trained in biotechnology, chemistry, gene technology and bioanalytics,” says Goldenbaum.
Solis BioDyne is also preparing to build a larger and more modern new office and production building on Palsa Street in Tartu. “We are starting to outgrow our current premises in Tartu Science Park because our staff and production volumes have multiplied over the past couple of years. We hope to move into the new building equipped with a state-of-the-art biotech research and development unit in a year’s time,” explains Goldenbaum.
Salim Essakali, who also has long-term experience from the biotechnology company QIAGEN and the manufacturer of medical devices Boston Scientific, will also start working as the Head of Global Sales and Marketing of Solis BioDyne on September 1. 2021.
He has conducted his Master of Science in Molecular Pathology, holds an MBA in Corporate Strategy, and has extensive management experience developing, commercializing, and life-cycle-managing in BioTech and MedTech field.
OÜ Solis BioDyne operating in Tartu Science Park is one of Estonia’s leading biotech companies developing and producing reagents. DNA polymerases, PCR Master Mixes, qPCR Mixes and reverse transcription reagents are highly valued across the globe. Majority of its exports end up in Europe and the United States of America. Solis BioDyne uses unique genetic modification within all products to make them stable at room temperature for 30 days, to provide more sustainable and cost-effective solutions. The company was established in 1995 and now employs over 60 people.
Further information:
Sigrid HänniMarketing and Communication ManagerSOLIS BIODYNE OÜA: Teaduspargi 9, 50411 Tartu, EstoniaT: +372 5682 5751E: sigrid.hanni@solisbiodyne.comW: www.solisbiodyne.com
This summer we got to collaborate with a fun project organized by the MINT Campus in Germany. Not only does MINT campus inspire children and young people about these topics but it also introduces young people to sustainable, innovative developments in current research and technology.
Whether you are studying the genetic material of plants, brains or viruses, the experiment usually starts with extracting RNA from the sample material. It would be incredibly useful to get all the RNA extracted instead of it getting destroyed by the RNases before even starting the cDNA synthesis step. But how can we protect the RNA when RNases are all around us? Let’s find out!
There aren’t many people who can lead teams as well as our Head of Quality and Product Management Eva-Maria does. She is like that red string on a mystery board connecting all the departments. If you would like to get a little closer to solving the great leadership puzzle that Eva-Maria has mastered, have a look at the following story.
On the 4th and 5th of June representatives from South Korea visited Tartu. Their primary focus was on exploring opportunities in the fields of biotechnology and medicine, seeking potential collaborators in Estonia. We had the great pleasure of meeting the delegation and sharing our knowledge on both days of the visit.
